Latest hypoparathyroidism Stories
DUBLIN, Jan. 23, 2015 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) notes the announcement today by NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) that the U.S.
An investigational parathyroid hormone replacement effectively treated a rare disorder characterized by low calcium and high phosphate levels in the blood.
During thyroidectomy (surgery to remove the thyroid gland), the technique surgeons use to identify an important nerve appears to make a difference in terms of complications such as impairment of the parathyroid glands (which make a hormone that controls calcium levels).
RARITAN, N.J., Nov. 1, 2010 /PRNewswire/ -- Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the VITROSÂ® intact Parathyroid Hormone (iPTH) Assay.
NPS Pharmaceuticals has reported positive interim data from an investigator-initiated Phase II proof-of-concept study of NPSP558, the proprietary recombinant full-length human parathyroid hormone for the treatment of hypoparathyroidism.
At the 30th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), positive interim data were presented from an investigator-initiated Phase 2 proof-of-concept study of NPSP558, the proprietary recombinant full-length human parathyroid hormone (PTH 1-84) under development by NPS Pharmaceuticals, Inc.
Fontus Pharmaceuticals, a specialty pharmaceutical company focused on nephrology and endocrinology, has acquired Rocaltrol from Roche Laboratories.
PARSIPPANY, N.J., June 16 /PRNewswire/ -- Fontus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on nephrology and endocrinology, announced today that it has acquired ROCALTROL(R) (calcitriol) from Roche Laboratories Inc.